Geron, Angiochem Enter License Pact
The deal will provide Geron (NASDAQ: GERN) with a worldwide exclusive license to Angiochem's proprietary peptide technology that facilitates the transfer of anti-cancer compounds across the blood-brain barrier to be used with tubulin disassembly inhibitors, including the Company's product candidate GRN1005. As a result of the Company's determination to discontinue the development of GRN1005 as described elsewhere in this Current Report on Form 8-K, on December 3, 2012, Geron provided notice to Angiochem that Geron is terminating the License Agreement. Termination of the License Agreement will be effective on June 1, 2013.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.